Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC β-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens : a pilot multicenter randomized controlled trial (MERINO-2)

• Main Authors: Stewart, Adam G., Paterson, David L., Young, Barnaby, Lye, David C., Davis, Joshua S., Schneider, Kellie, Yilmaz, Mesut, Dinleyici, Rumeysa, Runnegar, Naomi, Henderson, Andrew, Archuleta, Sophia, Kalimuddin, Shirin, Forde, Brian M., Chatfield, Mark D., Bauer, Michelle J., Lipman, Jeffrey, Harris-Brown, Tiffany, Harris, Patrick N. A.
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2021
• Subjects: Science::Medicine; Carbapenem; Clinical Trial
• Online Access: https://hdl.handle.net/10356/154068
• Institution: Nanyang Technological University

Background: Carbapenems are recommended treatment for serious infections caused by AmpC-producing gram-negative bacteria but can select for carbapenem resistance. Piperacillin-tazobactam may be a suitable alternative. Methods We enrolled adult patients with bloodstream infection due to chromoso...